An interventional study of symptom-focused rehabilitation and usual care in COVID-19 and Long-COVID, sponsored by Schön Klinik Berchtesgadener Land. Completed at 8 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-28.
Sponsored by Schön Klinik Berchtesgadener Land · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany — 14 open to participants now, 17 under way, 2 of them phase 3. Post-Acute COVID-19 Syndrome · Germany.
Among the 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany, this one is the 11th largest by enrollment of the 28 interventional ones that give a count, is one of 9 that started in 2022, is one of 20 with no phase, and was the 2nd registered.
606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
Browse Post-Acute COVID-19 Syndrome studies →14 of the 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany are open now. Recruiting first, the newest first:
University Hospital Schleswig-Holstein · Sites in Germany
Ages 18+
Eggensberger OHG · Sites in Germany
Ages 18+
Max-Planck-Institute of Psychiatry · Sites in Germany
Ages 18–65
Schön Klinik Berchtesgadener Land · Sites in Germany
Ages 18+
Hellenic Institute for the Study of Sepsis · Sites in Germany, Greece, Italy and 1 more country
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 3
First in 2018; this study’s year is marked. 9 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 132 is above the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Median enrollment 108 across the 28 interventional studies, 130 across the 13 observational. Of the 20 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 41 have an industry lead sponsor. The 10 most frequent:
Schön Klinik Berchtesgadener Land is the lead sponsor of 51 studies on the registry; 2 are open to participants now.
Schön Klinik Berchtesgadener Land has 3 studies filed under Post-Acute COVID-19 Syndrome — fewer than ten, so there is no comparison to draw.
5 of the studies in Post-Acute COVID-19 Syndrome with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07197138Max-Planck-Institute of PsychiatryIMPACT-D+: Immune-Modulating and Psychometric Effects of Accelerated TMS in Depression Plus Comorbid Post-COVID-19 Condition | 2027-01 |
| NCT07110714Eggensberger OHGEffects of Kneipp Hydrotherapy in Post-COVID-19 Patients | 2027-01-31 |
| NCT07013903Schön Klinik Berchtesgadener LandEffects of Hydrotherapy During Post-COVID-19 Rehabilitation | 2027-01-31 |
| NCT06510985University Hospital TuebingenTranscutaneous Vagus Nerve Stimulation (tVNS) for Improved Recovery After Exertion. | 2027-05 |
| NCT05638724Technical University of MunichMunich Long COVID Registry for Children, Adolescents, and Adults | 2027-07-20 |
Add all 5 to your calendar (.ics) → With an account.
Among the 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Inpatient, multimodal rehabilitation represents one of the most important interventions in the disease management of post/long COVID. Different professional societies, including the German Society of Pneumology and the European Respiratory Society, recommend rehabilitation intervention to reduce the sequelae of COVID-19. However, from the perspective of science and practice, there are relevant areas that have been insufficiently investigated and are essential for the treatment success of post/long COVID patients:
Therefore, post-COVID patients will be recruited at several post-COVID practices around Germany and randomized to receive (A) a rehabilitation program or (B) usual care. The primary objective of this randomized controlled trial (RCT) is to investigate whether a 3-week symptom-oriented, inpatient, multidisciplinary rehabilitation intervention, whose content focus is standardized according to cluster assignment (fatigue, cognition, soma), has a positive effect on the quality of life (primary outcome) in post-COVID syndrome patients compared to a usual care group (standard outpatient care). All study participants will be provided with a continuous telemonitoring system (SaniQ app) throughout the study period. After the interventional phase, there will be a 3 months follow-up assessment to evaluate the maintenance effects of COVID rehabilitation.
606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
This study's enrollment of 132 is above the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Browse Post-Acute COVID-19 Syndrome studies →Schön Klinik Berchtesgadener Land is the lead sponsor of 51 studies on the registry; 2 are open to participants now.
Compared within Post-Acute COVID-19 Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is COVID-19. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients in this arm will be referred to a 3-week inpatient comprehensive rehabilitation program. Initially, patients will be classified into one out of three clusters namely: Cluster A (Fatigue), Cluster B (cognition), or Cluster C (physical). The content of the rehabilitation program will be individually adapted according to the patient's most relevant symptom cluster.
Other: symptom-focused rehabilitation
Patients in this arm do not receive any intervention beyond usual care during the study phase. However, all patients in this group will get the opportunity to also receive a rehabilitation program after the study phase.
Other: usual care
Patients in this arm will be referred to a 3-week inpatient comprehensive rehabilitation program. Initially, patients will be classified into one out of three clusters namely: Cluster A (Fatigue), Cluster B (cognition), or Cluster C (physical). The content of the rehabilitation program will be individually adapted according to the patient's most relevant symptom cluster.
Patients in this arm do not receive any intervention beyond usual care during the study phase. However, all patients in this group will get the opportunity to also receive a rehabilitation program after the study phase.
Change from baseline Quality of life assessed by Short Form - 12 Questionnaire at week 4 and week 12
the scale of the physical and mental Health component summary score ranges from minimum 0 to maximum 100 points with higher scores indicating better quality of life
Time frame: baseline, week 4, week 12
Change from baseline COVID-related symptoms at week 4 and week 12
the number of COVID-symptoms will recorded as well as their intensity will be rated on a scale from 0 \[not relevant\] until 10 \[very severe symptom\].
Time frame: baseline, week 4, week 12
Change from baseline lung function at week 4 and week 12
following Parameters will be collected: forced expiratory volume in 1 sec, peak flow, forced vital capacity, total lung capacity, diffusion lung capacity for carbonmonoxide
Time frame: baseline, week 4, week 12
Change from baseline blood gas analysis at week 4 and week 12
following parameters will be collected at rest and at the end of an incremental cycle test: partial pressure for oxygen and carbon dioxide
Time frame: baseline, week 4, week 12
Change from baseline Cardiac Doppler echocardiography at week 4 and week 12
Left and right heart echocardiography will be performed
Time frame: baseline, week 4, week 12
Change from baseline laboratory parameters at week 4 and week 12
blood samples will be taken from venous blood
Time frame: baseline, week 4, week 12
Change from baseline exercise performance at week 4 and week 12
incremental cardiopulmonary exercise testing will be performed with spirometry
Time frame: baseline, week 4, week 12
Change from baseline health care service needs at week 4 and week 12
Number of visits at the general practitioner, pulmonologist, psychologist, physiotherapist, COVID-ambulance, hospital admission until the last visit will be recorded
Time frame: baseline, week 4, week 12
Change from baseline working capability at week 4 and week 12
number of days of incapacity to work until the last visit will be recorded
Time frame: baseline, week 4, week 12
Change from baseline sleep quality at week 4 and week 12
Sleep quality will be assessed by using the Pittsburgh Sleep Quality Index (total score ranges from 0 to 21 with higher scores indicating higher impairment)
Time frame: baseline, week 4, week 12
Change from baseline sleep quality at week 4 and week 12
daytime sleepiness will be assessed by using the Epworth Sleepiness Scale (total score ranges from 0 to 24 with higher scores indicating higher impairment)
Time frame: baseline, week 4, week 12
Change from baseline Depression status assessed by Patient Health Questionnaire 9
the total score ranges from 0 to 27 points with higher scores indicating worse Depression symptoms
Time frame: baseline, week 4, week 12
Change from baseline Anxiety status assessed by Generalized Anxiety Disorder Scale 7
the total score ranges from 0 to 21 points with higher scores indicating more anxiety symptoms
Time frame: baseline, week 4, week 12
Change from baseline resilience assessed by resilience scale 13
the total score ranges from 13 to 91 points with higher scores indicating higher resilience
Time frame: baseline, week 4, week 12
Change from baseline cognitive status assessed by Montreal Cognitive Assessment Test
the total score ranges from 0 to 30 points with higher scores indicating a better cognitive status
Time frame: baseline, week 4, week 12
Change from baseline dyspnea assessed by Modified Medical Research Counsil score at week 4 and week 12
the total score ranges from 0 to 4 points with higher scores indicating more dyspnea
Time frame: baseline, week 4, week 12
Change from baseline dysfunctional breathing assessed by Nijmegen breathing questionnaire at week 4 and week 12
the total score ranges from 0 to 64 points with higher scores indicating hyperventilation
Time frame: baseline, week 4, week 12
Change from baseline chronic fatigue syndrome assessed by fatigue assessment scale at week 4 and week 12
the total score ranges from 10 to 50 points with higher scores indicating more fatigue
Time frame: baseline, week 4, week 12
Change from baseline chronic fatigue syndrome assessed by canadian consensus criteria at week 12
the canadian consensus criteria indicate if patients developed a chronic fatigue syndrome/myalgic encephalomyelitis
Time frame: baseline, week 12
Change from baseline functional status assessed by post-COVID functional status scale at week 4 and week 12
the total score ranges from 0 to 4 points with higher scores indicating more impairment
Time frame: baseline, week 4, week 12
Change from baseline physical activity assessed by Garmin watch at week 4 and week 12
daily total steps per day will be recorded by a Garmin watch linked to the SaniQ App
Time frame: baseline, week 4, week 12
Change from baseline blood pressure assessed at week 4 and week 12
blood pressure will be measured at the upper arm using the Aponorm device
Time frame: baseline, week 4, week 12
Change from baseline oxygen saturation assessed by pulse oximeter at week 4 and week 12
Beurer pulse oximeter
Time frame: baseline, week 4, week 12
Change from baseline peak flow assessed by peak flow meter at week 4 and week 12
peak flow will be assessed by smart one spirometer
Time frame: baseline, week 4, week 12
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from May 2022 to primary completion in Jan 2024, 20 months.
Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's 20 months is above that.
Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Post-Acute COVID-19 Syndrome →
Schön Klinik Berchtesgadener Land